MetaCap

Larimar Therapeutics (LRMR) vs Puma Biotechnology (PBYI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Puma Biotechnology (PBYI) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 44.2% versus a loss of 11.8%. Over five years, PBYI leads with a +118.3% price change compared with -69.0% for LRMR. Puma Biotechnology is the larger company by market cap ($364.5 million vs $328.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LRMR-11.80%PBYI+44.17%
+139%+43%-53%
Nov 21, 20251 yearNov 20, 2026
LRMR-69.37%PBYI+106.14%
+238%+69%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LRMR versus PBYI key metrics
MetricLRMRPBYI
Share price$3.14$7.05
Market cap$328.55M$364.47M
1-day change-2.48%-0.98%
YTD return-17.59%+18.49%
1-year return-11.80%+44.17%
5-year return-68.97%+118.27%
P/E ratio (TTM)—15.33
Forward P/E—20.14
EPS (TTM)$-1.67$0.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$228.37M
Revenue growth (YoY)—-0.91%
Net income (latest FY)$-165.67M$31.11M
Gross margin—74.53%
Operating margin—16.33%
Net margin—13.62%
52-week high$6.42$11.50
52-week low$1.92$4.84
Distance from 52-week high-51.09%-38.70%
Analyst consensusstrong_buynone
Avg. price target upside+352.23%—
Average volume1.38M387.40K
Shares outstanding104.63M51.70M
Employees71179
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PBYI has outperformed LRMR by 56.0 percentage points over the past year.

About Larimar Therapeutics

LRMR stock →

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees

About Puma Biotechnology

PBYI stock →

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees

LRMR vs PBYI FAQ

Which is bigger, Larimar Therapeutics or Puma Biotechnology?

Puma Biotechnology (PBYI) is larger, with a market capitalization of $364.47M compared with $328.55M for Larimar Therapeutics (LRMR).

Which stock has performed better over the past year, LRMR or PBYI?

PBYI returned +44.17% over the past 12 months, compared with -11.80% for LRMR (price return, excluding dividends). Past performance does not predict future results.

Are Larimar Therapeutics and Puma Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons